International Clinical Trial: Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535489) titled 'Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)' on April 10.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Nanjing Immunophage Biotech Co., Ltd

Condition: Moderately to Severely Active Ulcerative Colitis (UC)

Intervention: Drug: IPG11406

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 7, 2026

Target Sample Size: 144

Countries of Recruitmen...